Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Solid Tumors 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Advanced Malignant Solid Neoplasm 2Vaginal Neoplasms 1Triple-negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Previously Treated Non Small Cell Lung Cancer 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pinealoma 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Metastatic Pancreatic Adenocarcinoma 1Meningeal Carcinomatosis 1Medulloblastoma 1Lymphoid Interstitial Pneumonia 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1

Interventions

adavosertib 1Paclitaxel 1Gemcitabine 1Carboplatin 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation × adavosertib × Clear all
NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AstraZeneca

Phase 2 Completed
95 enrolled 61 charts
Gynecologic

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡